Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Podcasts|October 7, 2026

The BioPharm Brief: Advancing ADCs, Biosimilars and CAR-T Therapies

New regulatory decisions, manufacturing partnerships, and financing pressures are reshaping access, supply, and development pathways for emerging advanced therapies.

Welcome to The BioPharm Brief, your daily snapshot of the latest developments shaping biopharmaceutical research, clinical progress, and drug development. Today’s update looks at new FDA breakthrough designations for a targeted cancer therapy, expanded biosimilar manufacturing capacity, the US launch of an interchangeable biosimilar, and a setback for allogeneic chimeric antigen receptor T cell (CAR-T) therapy development.

AbbVie’s investigational antibody-drug conjugate (ADC) Temab-A has received 2 FDA breakthrough therapy designations, covering colorectal cancer and non-small cell lung cancer. The c-Met-directed ADC combines a monoclonal antibody with a topoisomerase 1 inhibitor payload. In a heavily pretreated colorectal cancer population, Temab-A produced a 15.6% overall response rate and a 74.6% disease control rate. The designations could help accelerate development of a targeted approach for patients with limited treatment options, although the therapy remains investigational.

Moving from clinical development to manufacturing, Alvotech has partnered with LOTTE Biologics to produce drug substance for multiple antibody biosimilars at LOTTE’s 40,000-L Syracuse, NY, facility. The agreement expands Alvotech’s US manufacturing footprint and global supply network, although the specific products and commercial timeline have not been disclosed. Commercial supply will depend on technology transfer, manufacturing qualification, and regulatory approvals.

That focus on expanding biosimilar supply also connects with the US launch of Omlyclo, Celltrion’s omalizumab-igec. The FDA-approved interchangeable biosimilar to Xolair is now commercially available across 4 approved indications, including asthma, chronic rhinosinusitis with nasal polyps, food allergy, and chronic spontaneous urticaria. Its availability adds another treatment option in allergy and immunology and could expand access to an established biologic therapy.

Meanwhile, Caribou Biosciences is discontinuing development of its allogeneic CAR-T programs vispa-cel and CB-011 while evaluating strategic alternatives, including a potential sale or merger. The decision reflects financing challenges facing allogeneic CAR-T despite encouraging early clinical results, underscoring the gap between promising cell therapy data and the capital required to advance programs toward late-stage development.

These latest developments highlight how clinical evidence, regulatory decisions, manufacturing capacity, and financing conditions continue to shape which therapies advance through the biopharmaceutical pipeline.

Thanks for listening to The BioPharm Brief. For more analysis and expert insights, please visit www.BioPharmInternational.com.

Key takeaways

  • Temab-A earned 2 FDA breakthrough designations for difficult-to-treat solid tumors.
  • Alvotech and LOTTE Biologics are expanding US capacity for antibody biosimilars.
  • Omlyclo expands interchangeable biosimilar options, while Caribou’s exit highlights challenges for allogeneic CAR-T development.


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.